Evidence map›Paper›PMID 28846108›Full record

ArticleOncogene2017

Runx3 plays a critical role in restriction-point and defense against cellular transformation.

X-Z Chi, J-W Lee, Y-S Lee, I Y Park, Y Ito, S-C Bae

Open access · hybridAbstract read
In one paragraph

Article in Oncogene, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.5field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Cells · 2023
    Review
  5. Epigenetic Abnormalities in Chondrosarcoma.International journal of molecular sciences · 2023
    Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Molecules and cells · 2020
    Article
  11. Article
  12. Haematologica · 2020
    Article
  13. Role of RUNX Family Members in GMolecules and cells · 2020
    Review
  14. Review
  15. Article
  16. Article
  17. Functional relationship between p53 and RUNX proteins.Journal of molecular cell biology · 2019
    Review
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

X-Z ChiDepartment of Biochemistry, School of Medicine, and Institute for Tumor Research, Chungbuk National University, Cheongju, South Korea.
J-W LeeDepartment of Biochemistry, School of Medicine, and Institute for Tumor Research, Chungbuk National University, Cheongju, South Korea.
Y-S LeeDepartment of Biochemistry, School of Medicine, and Institute for Tumor Research, Chungbuk National University, Cheongju, South Korea.
I Y ParkCollege of Pharmacy, Chungbuk National University, Cheongju, South Korea.
Y ItoCancer Science Institute of Singapore, National University of Singapore, Center for Translational Medicine, Singapore, Singapore.
S-C BaeDepartment of Biochemistry, School of Medicine, and Institute for Tumor Research, Chungbuk National University, Cheongju, South Korea.
Chungbuk National University · KRNational University Cancer Institute, Singapore · SG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The restriction (R)-point decision is fundamental to normal differentiation and the G

Indexed as

Cell Transformation, NeoplasticAnimalsBromodomain Containing ProteinsCarcinogenesisCore Binding Factor Alpha 3 SubunitCyclin-Dependent Kinase Inhibitor p21Genes, rasHEK293 CellsHumansMiceProtein Serine-Threonine KinasesRetinoblastoma ProteinTranscription FactorsBRD2 protein, humanBromodomain Containing ProteinsCDKN1A protein, humanCore Binding Factor Alpha 3 SubunitCyclin-Dependent Kinase Inhibitor p21Protein Serine-Threonine KinasesRetinoblastoma ProteinTranscription Factors

Identifiers

PMID28846108
PMCPMC5735299
OpenAlexW2746499715

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.